Dr. Brian T. Spears, MD
Emergency Medicine (Emergency Medicine Physician)
At a glance
- In the NPI registry since
- 2010
Licensed in Texas since 2013, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medicine Physician primary
TX license P6092 (first issued 2013; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $122 in total to this clinician.
| Viiv Healthcare Company | $122 |
|---|
| Food and Beverage | $122 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $5,600,763 in research payments for these studies, mostly to the institutions running them.
- A phase 1 double-blind (sponsor-unblinded), placebo-controlled, random
Viiv Healthcare Company - A phase 1, randomized, double-blinded, placebo-controlled, parallel gr
GlaxoSmithKline, LLC. - A phase 1, single center, single dose, open-label, randomized, 2-way c
GlaxoSmithKline, LLC. - Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Sanofi Pasteur Inc. · Completed · NCT06695117 - A phase i, multi-centre, open-label, single dose escalation study to e
Viiv Healthcare Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.